Market News

Abbott Labs (ABT)

Abbott Labs was granted 510(k) clearance by the FDA for an antibody cyclic-citrulinated peptide, or anti-CCP assay, to run on its ARCHITECT immunoassay analyzers.
Many patients with RA develop an immune response against proteins containing citrulline long before they present symptoms of the disease. Studies show detecting the level of these antibodies earlier in the disease continuum, in conjunction with other clinical information, is critical to the early diagnosis of the disease.

Oct 20 · 12:25:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Pfizer (PFE)

Pfizer Inc. on Tuesday posted a higher third-quarter profit despite the recession, as sharp cost cuts made up for a dip in sales.
The maker of cholesterol fighter Lipitor, impotence treatment Viagra and smoking cessation drug Chantix slashed costs on everything from manufacturing and marketing to research and development to produce a profit of $2.88 billion. That was up 26 percent from $2.28 billion a year earlie

Oct 20 · 12:24:00 PM · Source: AP
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Forest Laboratories (FRX)

Forest Laboratories said quarterly revenues increased to $1,063,934,000 versus year prior period of 992,506,000. Net income for the quarter was $186,662,000 vs. $244,086,000

Oct 20 · 10:55:00 AM · Source: Business Wire
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Merck (MRK)

Merck & Co., Inc. (MRK) announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for use in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.
FDA approval is the first step in an important two-step process. The next step in the process is an Advisory Committee on Immunization Practices vote on whether to recommend administration of GARDASIL for use in males.

Oct 16 · 2:04:00 PM · Source: Business Wire
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb slashed about 25% of its sales force for the antipsychotic Abilify on Friday.
The job cuts resulted from an evaluation the New York drug maker conducted after it extended its co-marketing pact with Otsuka Corp. for Abilify earlier this year. Most major drug companies have steadily reduced their sales forces in recent years to save costs and address doctors' complaints that they were being bombarded by too many sales representatives. The company declined to specify how many jobs were cut, saying the size of its Abilify sales force was proprietary.

Oct 16 · 11:18:00 AM · Source: The Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Gilead Sciences (GILD)

Gilead Sciences Chairman and CEO John C. Martin sold 100,000 shares of his company’s stock at an average price of $45.40 per share on October 13.

Oct 15 · 2:42:00 PM · Source: Guru Focus
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Baxter International (BAX)

Baxter International reported earnings of $0.87 per share versus $0.74 per share for the year ago quarter. Sales for the quarter were $3.15 billion which is flat for the year ago quarter.
Baxter attributes the earnings growth on flat sales to lowered expenses, improved margins, and a stock buyback program.

Oct 15 · 11:31:00 AM · Source: Market Watch
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Amgen (AMGN)

Amgen’s new osteoporosis drug, Denosumab, which is scheduled for FDA approval on October 19, may now be delayed.
Denosumab is viewed by some as the most significant biotech launch in years. Analysts are now expecting a possible 3-month delay in approval because the FDA may want more time to study the drug’s safety record.

Oct 15 · 11:17:00 AM · Source: Easy Bourse
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Previous · Next